Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Evaluate the relationship between EGFR mutation status and clinical outcomes reported in …
Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay, S Tang… - The Oncologist, 2010 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Learning Objectives</jats: title><
jats: p> After completing this course, the reader will be able to: Evaluate the relationship …
jats: p> After completing this course, the reader will be able to: Evaluate the relationship …
Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).
MH COHEN, JR JOHNSON… - …, 2010 - search.ebscohost.com
Abstract On April 16, 2010, the US Food and Drug Administration (FDA) approved erlotinib
tablets (Tarceva; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of …
tablets (Tarceva; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of …
[PDF][PDF] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non‐Small Cell Lung Cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay… - The …, 2010 - Wiley Online Library
Learning Objectives After completing this course, the reader will be able to: Evaluate the
relationship between EGFR mutation status and clinical outcomes reported in this study …
relationship between EGFR mutation status and clinical outcomes reported in this study …
[HTML][HTML] Approval Summary: Erlotinib Maintenance Therapy of Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay, S Tang… - The …, 2010 - ncbi.nlm.nih.gov
Abstract On April 16, 2010, the US Food and Drug Administration (FDA) approved erlotinib
tablets (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of …
tablets (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
MH Cohen, JR Johnson, S Chattopadhyay, S Tang… - The …, 2010 - europepmc.org
ABSTRACT On April 16, 2010, the US Food and Drug Administration (FDA) approved
erlotinib tablets (Tarceva; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment …
erlotinib tablets (Tarceva; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)
MH Cohen, JR Johnson, S Chattopadhyay, S Tang… - 2010 - pubmed.ncbi.nlm.nih.gov
On April 16, 2010, the US Food and Drug Administration (FDA) approved erlotinib tablets
(Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients …
(Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients …
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
MH Cohen, JR Johnson, S Chattopadhyay, S Tang… - The …, 2010 - europepmc.org
On April 16, 2010, the US Food and Drug Administration (FDA) approved erlotinib tablets
(Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients …
(Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY) for maintenance treatment of patients …